Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population

Cai Mei Zheng, Jia Yi Wang, Tzu Ting Chen, Yun Chun Wu, Yi Lien Wu, Hsin Ting Lin, Sheng Po Chiu, Tian Jong Chang, Jing Quan Zheng, Nain Feng Chu, Yu Me Lin, Sui Lung Su, Kuo Cheng Lu, Jin Shuen Chen, Fung Chang Sung, Chien Te Lee, Yu Yang, Shang Jyh Hwang, Ming Cheng Wang, Yung Ho Hsu & 4 others Hung Yi Chiou, Senyeong Kao, Mei Yi Wu, Yuh Feng Lin

研究成果: 雜誌貢獻文章

摘要

It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m 2 /yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.
原文英語
文章編號2694
期刊Scientific Reports
9
發行號1
DOIs
出版狀態已發佈 - 十二月 1 2019

指紋

Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Kidney
Population
Disease Progression
Hypertension
Control Groups
Longitudinal Studies
Dialysis
Cohort Studies
Odds Ratio
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • General

引用此文

Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. / Zheng, Cai Mei; Wang, Jia Yi; Chen, Tzu Ting; Wu, Yun Chun; Wu, Yi Lien; Lin, Hsin Ting; Chiu, Sheng Po; Chang, Tian Jong; Zheng, Jing Quan; Chu, Nain Feng; Lin, Yu Me; Su, Sui Lung; Lu, Kuo Cheng; Chen, Jin Shuen; Sung, Fung Chang; Lee, Chien Te; Yang, Yu; Hwang, Shang Jyh; Wang, Ming Cheng; Hsu, Yung Ho; Chiou, Hung Yi; Kao, Senyeong; Wu, Mei Yi; Lin, Yuh Feng.

於: Scientific Reports, 卷 9, 編號 1, 2694, 01.12.2019.

研究成果: 雜誌貢獻文章

Zheng, Cai Mei ; Wang, Jia Yi ; Chen, Tzu Ting ; Wu, Yun Chun ; Wu, Yi Lien ; Lin, Hsin Ting ; Chiu, Sheng Po ; Chang, Tian Jong ; Zheng, Jing Quan ; Chu, Nain Feng ; Lin, Yu Me ; Su, Sui Lung ; Lu, Kuo Cheng ; Chen, Jin Shuen ; Sung, Fung Chang ; Lee, Chien Te ; Yang, Yu ; Hwang, Shang Jyh ; Wang, Ming Cheng ; Hsu, Yung Ho ; Chiou, Hung Yi ; Kao, Senyeong ; Wu, Mei Yi ; Lin, Yuh Feng. / Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. 於: Scientific Reports. 2019 ; 卷 9, 編號 1.
@article{23a898f0d3254e3197e53b1e680e7e6d,
title = "Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population",
abstract = "It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m 2 /yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70{\%} of the control group and 25.09{\%} of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95{\%} confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.",
author = "Zheng, {Cai Mei} and Wang, {Jia Yi} and Chen, {Tzu Ting} and Wu, {Yun Chun} and Wu, {Yi Lien} and Lin, {Hsin Ting} and Chiu, {Sheng Po} and Chang, {Tian Jong} and Zheng, {Jing Quan} and Chu, {Nain Feng} and Lin, {Yu Me} and Su, {Sui Lung} and Lu, {Kuo Cheng} and Chen, {Jin Shuen} and Sung, {Fung Chang} and Lee, {Chien Te} and Yu Yang and Hwang, {Shang Jyh} and Wang, {Ming Cheng} and Hsu, {Yung Ho} and Chiou, {Hung Yi} and Senyeong Kao and Wu, {Mei Yi} and Lin, {Yuh Feng}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-38991-z",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population

AU - Zheng, Cai Mei

AU - Wang, Jia Yi

AU - Chen, Tzu Ting

AU - Wu, Yun Chun

AU - Wu, Yi Lien

AU - Lin, Hsin Ting

AU - Chiu, Sheng Po

AU - Chang, Tian Jong

AU - Zheng, Jing Quan

AU - Chu, Nain Feng

AU - Lin, Yu Me

AU - Su, Sui Lung

AU - Lu, Kuo Cheng

AU - Chen, Jin Shuen

AU - Sung, Fung Chang

AU - Lee, Chien Te

AU - Yang, Yu

AU - Hwang, Shang Jyh

AU - Wang, Ming Cheng

AU - Hsu, Yung Ho

AU - Chiou, Hung Yi

AU - Kao, Senyeong

AU - Wu, Mei Yi

AU - Lin, Yuh Feng

PY - 2019/12/1

Y1 - 2019/12/1

N2 - It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m 2 /yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.

AB - It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m 2 /yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.

UR - http://www.scopus.com/inward/record.url?scp=85062073717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062073717&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-38991-z

DO - 10.1038/s41598-019-38991-z

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2694

ER -